Cellebrite DI Ltd (NASDAQ: CLBT)’s stock price has increased by 2.60 compared to its previous closing price of 17.68. However, the company has seen a 9.81% increase in its stock price over the last five trading sessions. zacks.com reported 2024-10-08 that Cellebrite DI Ltd. (CLBT) is at a 52-week high, but can investors hope for more gains in the future?
Is It Worth Investing in Cellebrite DI Ltd (NASDAQ: CLBT) Right Now?
The 36-month beta value for CLBT is at 1.50. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CLBT is 61.31M, and currently, shorts hold a 5.30% of that float. The average trading volume for CLBT on October 09, 2024 was 1.37M shares.
CLBT’s Market Performance
The stock of Cellebrite DI Ltd (CLBT) has seen a 9.81% increase in the past week, with a 10.48% rise in the past month, and a 56.24% gain in the past quarter. The volatility ratio for the week is 3.77%, and the volatility levels for the past 30 days are at 3.27% for CLBT. The simple moving average for the past 20 days is 5.85% for CLBT’s stock, with a 49.25% simple moving average for the past 200 days.
Analysts’ Opinion of CLBT
Many brokerage firms have already submitted their reports for CLBT stocks, with Needham repeating the rating for CLBT by listing it as a “Buy.” The predicted price for CLBT in the upcoming period, according to Needham is $13.50 based on the research report published on March 28, 2024 of the current year 2024.
BofA Securities gave a rating of “Buy” to CLBT, setting the target price at $12 in the report published on February 16th of the current year.
CLBT Trading at 13.08% from the 50-Day Moving Average
After a stumble in the market that brought CLBT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.78% of gains for the given period.
Volatility was left at 3.27%, however, over the last 30 days, the volatility rate increased by 3.77%, as shares surge +9.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.09% upper at present.
During the last 5 trading sessions, CLBT rose by +9.81%, which changed the moving average for the period of 200-days by +121.49% in comparison to the 20-day moving average, which settled at $17.14. In addition, Cellebrite DI Ltd saw 109.47% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLBT starting from YOSEF CARMIL, who proposed sale 100,000 shares at the price of $17.51 back on Sep 16 ’24. After this action, YOSEF CARMIL now owns shares of Cellebrite DI Ltd, valued at $1,751,000 using the latest closing price.
Ben-Peretz Leeor, the Officer of Cellebrite DI Ltd, proposed sale 8,919 shares at $16.95 during a trade that took place back on Sep 04 ’24, which means that Ben-Peretz Leeor is holding shares at $151,177 based on the most recent closing price.
Stock Fundamentals for CLBT
Current profitability levels for the company are sitting at:
- 0.14 for the present operating margin
- 0.84 for the gross margin
The net margin for Cellebrite DI Ltd stands at -0.29. The total capital return value is set at 0.16. Equity return is now at value -1768.51, with -21.03 for asset returns.
Based on Cellebrite DI Ltd (CLBT), the company’s capital structure generated -0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 8.36. The debt to equity ratio resting at -0.29. The interest coverage ratio of the stock is 0.34.
Currently, EBITDA for the company is 43.29 million with net debt to EBITDA at -1.58. When we switch over and look at the enterprise to sales, we see a ratio of 10.15. The receivables turnover for the company is 5.13for trailing twelve months and the total asset turnover is 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.73.
Conclusion
In conclusion, Cellebrite DI Ltd (CLBT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
